Date Title
September 17, 2018
Realm Therapeutics - Corporate Update and Hiring of Advisor

RNS Number : 8941A Realm Therapeutics PLC 17 September 2018   THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULA TION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY

August 14, 2018
Realm Therapeutics - Half-year Report

RNS Number : 7159X Realm Therapeutics PLC 14 August 2018   THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULA TION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY

August 8, 2018
Realm Therapeutics - Presents at Wedbush PacGrow Healthcare Conference

RNS Number : 1132X Realm Therapeutics PLC 08 August 2018   Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference     MALVERN, PA , August 8, 2018 - Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel

August 7, 2018
Realm Therapeutics - Notice of Results

RNS Number : 9887W Realm Therapeutics PLC 07 August 2018       Realm Therapeutics to Report First Half 2018 Financial Results     MALVERN, PA , August 7, 2018 - Realm Therapeutics plc (NASDAQ:RLM / AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in

July 16, 2018
Realm Therapeutics - Holding(s) in Company
RNS Number : 8036U Realm Therapeutics PLC 16 July 2018   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
July 10, 2018
Realm Therapeutics - Pre-Clinical Study in Atopic Dermatitis
RNS Number : 0857U Realm Therapeutics PLC 10 July 2018     Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis     MALVERN, PA , July 10, 2018 - Realm Therapeutics plc (NASDAQ:RLM /
July 4, 2018
Realm Therapeutics - SEC registration effective NASDAQ listing approved
RNS Number : 5069T Realm Therapeutics PLC 04 July 2018   Realm Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares   MALVERN, PA , July 4, 2018 - Realm Therapeutics plc (AIM: RLM; Nasdaq: RLM) (the "Company") a
June 14, 2018
Realm Therapeutics - Result of AGM
RNS Number : 4116R Realm Therapeutics PLC 14 June 2018   Realm Therapeutics Announces Results of 2018 Annual General Meeting   MALVERN, PA , June 14, 2018 - Realm Therapeutics plc (AIM: RLM) a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated
May 31, 2018
Realm Therapeutics - Realm to Present at June Investor Conferences
RNS Number : 7573P Realm Therapeutics PLC 31 May 2018   Realm Therapeutics to Present at June Investor Conferences   MALVERN, PA , May 31, 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today
May 24, 2018
Realm Therapeutics - Enrollment complete for Phase 2 study of PR022
RNS Number : 1054P Realm Therapeutics PLC 24 May 2018   Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis   Company Further Strengthens IP Portfolio with New USPTO Notice of Allowance   Reiterates Plans to File an Initial New Drug (IND) Application for PR022 in
Displaying 1 - 10 of 25

Search Investor Relations